National Center for Injury Prevention and Control/Initial Review Group, (NCIPC/IRG), 7281 [2010-3047]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices
Dated: February 12, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[FR Doc. 2010–3036 Filed 2–17–10; 8:45 am]
BILLING CODE 4160–01–S
National Center for Injury Prevention
and Control/Initial Review Group,
(NCIPC/IRG)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Translating
Research Into Action for Diabetes
(TRIAD) Legacy Study, Funding
Opportunity Announcement (FOA) DP
10–005, Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Time and Date: 11 a.m.–5 p.m., March 31,
2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘TRIAD Legacy Study, FOA DP
10–005.’’
Contact Person for More Information: Don
Blackman, PhD, Scientific Review Officer,
National Center for Chronic Disease and
Health Promotion, Office of the Director,
Extramural Research Program Office, 4770
Buford Highway, NE., Mailstop K–92,
Atlanta, GA 30341, telephone: (770) 488–
3023, e-mail: DBlackman@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 10, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–3064 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
VerDate Nov<24>2008
14:39 Feb 17, 2010
Jkt 220001
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned review group:
Time and Date: 12:30 p.m.–4 p.m.,
March 3, 2010 (closed).
Place: Teleconference.
Status: The meetings will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5, U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Section 10(d)
of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and
Human Services, and the Director, CDC,
concerning the scientific and technical
merit of grant and cooperative
agreement applications received from
academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct
research that will build the scientific
base for the prevention of unintentional
poisonings from drug overdoses in the
adult population.
Matters to be Discussed: The meeting
will include the review, discussion, and
evaluation of applications intended to
encourage exploratory/developmental
research in unintentional childhood
injury. Requests for Applications are
related to the following individual
research announcement: CE10–002
Unintentional Poisoning from
Prescription Drug Overdoses in Adults
(R21).
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
J. Felix Rogers, PhD, M.P.H., Telephone
(770) 488–4334, NCIPC, CDC, 4770
Buford Highway, NE., Mail Stop F63,
Atlanta, Georgia 30341–3724. The
Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
7281
Dated: February 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–3047 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Pediatric Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Pediatric
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on Monday, March 22, 2010, from
8 a.m. to 6 p.m.
Location: Bethesda Marriott Hotel,
5151 Pooks Hill Rd., Bethesda, MD.,
20814.
Contact Person: Doreen Kezer, Office
of the Commissioner, Food and Drug
Administration, 5600 Fishers Lane (HF–
33), rm. 14–65, Rockville, MD 20857,
301–827–1249, e-mail:
Doreen.Kezer@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
8732310001. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The Pediatric Advisory
Committee will meet to discuss
pediatric-focused safety reviews, as
mandated by the Best Pharmaceuticals
for Children Act and the Pediatric
Research Equity Act, for: Anthelios 40,
Cardiolite (technetium Tc-99), Nasacort
AQ (triamcinolone), Viramune
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 75, Number 32 (Thursday, February 18, 2010)]
[Notices]
[Page 7281]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-3047]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Injury Prevention and Control/Initial Review
Group, (NCIPC/IRG)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
review group:
Time and Date: 12:30 p.m.-4 p.m., March 3, 2010 (closed).
Place: Teleconference.
Status: The meetings will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5,
U.S.C., and the Determination of the Director, Management Analysis and
Services Office, CDC, pursuant to Section 10(d) of Public Law 92-463.
Purpose: This group is charged with providing advice and guidance
to the Secretary, Department of Health and Human Services, and the
Director, CDC, concerning the scientific and technical merit of grant
and cooperative agreement applications received from academic
institutions and other public and private profit and nonprofit
organizations, including State and local government agencies, to
conduct research that will build the scientific base for the prevention
of unintentional poisonings from drug overdoses in the adult
population.
Matters to be Discussed: The meeting will include the review,
discussion, and evaluation of applications intended to encourage
exploratory/developmental research in unintentional childhood injury.
Requests for Applications are related to the following individual
research announcement: CE10-002 Unintentional Poisoning from
Prescription Drug Overdoses in Adults (R21).
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: J. Felix Rogers, PhD, M.P.H.,
Telephone (770) 488-4334, NCIPC, CDC, 4770 Buford Highway, NE., Mail
Stop F63, Atlanta, Georgia 30341-3724. The Director, Management
Analysis and Services Office has been delegated the authority to sign
Federal Register notices pertaining to announcements of meetings and
other committee management activities for both CDC and the Agency for
Toxic Substances and Disease Registry.
Dated: February 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-3047 Filed 2-17-10; 8:45 am]
BILLING CODE 4163-18-P
